QUESTION: If I suspect blastomycosis, should I order the antigen or the antibody test?
ANSWER: The MVista® Blastomyces Antigen Quantitative EIA (Test Code 316) is preferred for diagnosis of blastomycosis. We also offer the MVista® Blastomyces Canine IgG Antibody EIA (Test Code 330) which may be useful as a follow-up test in cases with suspected false negative or low positive antigen results. In cases with localized disease presentation (e.g., suspected ocular blastomycosis, solitary bone lesions, etc.), testing both antigen and antibody will likely improve sensitivity as we have observed more false negative antigen results in such cases. The antigen test may be used as a marker of therapeutic efficacy; therefore, obtaining a baseline urine antigen concentration is useful even in cytopathology or histopathology proven cases.
QUESTION: What is the preferred specimen for the antigen tests?
ANSWER: Urine is the preferred specimen. But 4% are positive only in serum (MiraVista)[1
QUESTION: What is the sensitivity and specificity of the antigen and antibody tests? (Table 1)
ANSWER: The sensitivity of antigen in urine is about 90% [2
QUESTION: Do you have a fungal panel?
ANSWER: We do not but we have a strategy based on endemic pattern, Table 2. Send both urine and serum specimens, requesting the primary test for your endemic area. Urine and serum should be tested for antigen as urine alone misses up to 20% of cases of blastomycosis. Request that if the primary test is negative to order the secondary tests.
QUESTION: Is there cross reactivity between the Blasto and Histo antigen tests?
ANSWER: Yes, nearly complete (99%) cross-reactivity occurs in histoplasmosis and blastomycosis, and the discrepancies are in the low positive range [7
QUESTION: I received a negative result for the Blasto antigen test. Can the antigen test be falsely negative?
ANSWER: Antigen concentration correlates with the severity of the infection, and results are almost always positive in moderately-severe or severe blastomycosis. Antigen tests may initially be negative in mild or localized cases and those presenting with brief duration of illness (1-2 weeks); therefore, a negative result does not exclude the diagnosis. In addition, nearly complete cross-reactivity occurs between antigen detection in histoplasmosis and blastomycosis, and current antigen tests cannot differentiate the two systemic fungal infections: There is no need to order testing for both antigens.
QUESTION: If my practice is located an area that is endemic for both blastomycosis and histoplasmosis, which antigen test should I submit?
ANSWER: Due to cross reactivity, it is unnecessary to test for both. Blastomycosis is more likely if bone or skin lesions are present. For canine patients with GI signs, histoplasmosis would be more likely. Cats are much more likely to have histoplasmosis. Histoplasma antigen testing would be recommended in those cases. Continue to order the test that was positive at baseline for monitoring response to treatment. Differentiation of the two infections is unnecessary, as treatment and monitoring are similar.
QUESTION: I received an antigen result that says “Positive, Below the Limit of Quantification (BLQ)”. What does this mean?
ANSWER: A BLQ result is a very low positive (<0.2 ng/mL). Results below 1 ng/mL may be truly positive or falsely positive. The result is likely to be truly positive if the clinical findings are consistent with blastomycosis. Testing for Blastomyces IgG antibodies (or Blastomyces and Histoplasma antibodies in areas were both are endemic) by EIA may help differentiate true from false-positive results. Repeat antigen testing is also recommended if the findings progress.
QUESTION: I am treating a patient for blastomycosis and the antigen concentration is not decreasing or is increasing. Is there a problem?
ANSWER: Yes, the antigen concentration declines with successful therapy. Some reasons for a failure to decrease include the following:
- Use of less effective antifungal: Non-FDA approved itraconazole (not compounded powder form of itraconazole) or fluconazole
- Subtherapeutic FDA approved itraconazole serum level (<2 mcg/mL). Obtain consultation if the antigen is not declining after 3 months of treatment
QUESTION: How often should antigen concentration be determined?
ANSWER: Antigen should be tested in urine at 3-month intervals during treatment, at 6 and 12 months after stopping treatment and any time the clinical findings suggest recurrence. And if the urine antigen is “Above Limit of Quantification, ALQ” (>14.7ng/mL), serum should be tested instead. When the serum antigen is negative, resume monitoring urine antigen until negative.
QUESTION: Should the antigen test be negative at the end of therapy?
ANSWER: The patient should be treated until the antigen result is negative. Testing for antigenuria about every three months during and for 6-12 months after stopping therapy, and any time that clinical signs suggest recurrence, is recommended. Obtain consultation if the antigen is still positive after 12 months of treatment.
QUESTION: What are the criteria for discontinuing treatment?
ANSWER: Treat all patients for at least 6 months and until:
- The clinical findings have resolved
- The radiographic or other imaging findings have resolved or improved significantly and are thought to represent residual scarring (unchanged on at least 2 occasions)
- The antigen is negative
- If the antigen is not decreasing during the first 3 months of treatment, obtain consultation to determine if the treatment is effective (verify using FDA approved itraconazole)
- If the antigen remains positive, although lower concentrations after 12 months of treatment obtain consultation to determine whether to modify or stop treatment
If you have questions, please call for a consult. 317-856-2681
- [Internal unpublished data]
- Spector, D., et al., Antigen and antibody testing for the diagnosis of blastomycosis in dogs. J Vet. Intern Med, 2008. 22(4): p. 839-843.
- Foy, D.S., et al., Serum and urine blastomyces antigen concentrations as markers of clinical remission in dogs treated for systemic blastomycosis. J. Vet. Intern. Med, 2014. 28(2): p. 305-310.
- Mourning, A.C., et al., Evaluation of an enzyme immunoassay for antibodies to a recombinant Blastomyces adhesin-1 repeat antigen as an aid in the diagnosis of blastomycosis in dogs. J Am Vet Med Assoc, 2015. 247(10): p. 1133-8.
- Hanzlicek, A.S., et al., Antigen Concentrations as an Indicator of Clinical Remission and Disease Relapse in Cats with Histoplasmosis. J Vet Intern Med, 2016. 30(4): p. 1065-73.
- Cunningham, L., et al., Sensitivity and Specificity of Histoplasma Antigen Detection by Enzyme Immunoassay. J Am Anim Hosp Assoc, 2015. 51(5): p. 306-10.
- Connolly, P., et al., Blastomyces dermatitidis Antigen Detection by Quantitative Enzyme Immunoassay. Clin. Vaccine Immunol, 2012. 19(1): p. 53-56.